BRPI0413848A - composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, método para prevenir inflamação e apoptose, e, uso de composto inibidor de caspase, ou de seu sal, ou de seu estereoisÈmero - Google Patents

composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, método para prevenir inflamação e apoptose, e, uso de composto inibidor de caspase, ou de seu sal, ou de seu estereoisÈmero

Info

Publication number
BRPI0413848A
BRPI0413848A BRPI0413848-1A BRPI0413848A BRPI0413848A BR PI0413848 A BRPI0413848 A BR PI0413848A BR PI0413848 A BRPI0413848 A BR PI0413848A BR PI0413848 A BRPI0413848 A BR PI0413848A
Authority
BR
Brazil
Prior art keywords
compound
apoptosis
preventing inflammation
preparing
therapeutic composition
Prior art date
Application number
BRPI0413848-1A
Other languages
English (en)
Inventor
Hye-Kyung Chang
Yeon-Soo Oh
Cheol-Won Park
Yong-Jin Jang
Tae-Kyo Park
Sung-Sub Kim
Min-Jung Kim
Mi-Jeong Park
Jung-Gyu Park
Hee-Dong Park
Kyeong-Sik Min
Tae-Soo Lee
Sang-Kyun Lee
Soo-Hyeon Kim
Hee-Kyung Jeong
Sun-Hwa Lee
Hwa-Dong Kim
Ae-Ri Kim
Ki-Sook Park
Hyun-Ik Shin
Hyeong-Wook Choi
Kyu-Woong Lee
Jae-Hoon Lee
Tae-Ho Heo
Ho-Jun Kim
Tae-Sik Kwon
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BRPI0413848A publication Critical patent/BRPI0413848A/pt
Publication of BRPI0413848B1 publication Critical patent/BRPI0413848B1/pt
Publication of BRPI0413848B8 publication Critical patent/BRPI0413848B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTO, PROCESSO PARA PREPARAR O COMPOSTO, COMPOSIçãO TERAPêUTICA PARA PREVENIR INFLAMAçãO E APOPTOSE, MéTODO PARA PREVENIR INFLAMAçãO E APOPTOSE, E, USO DE COMPOSTO INIBIDOR DE CASPASE, OU DE SEU SAL, OU DE SEU ESTEREOISÈMERO". A presente invenção refere-se a um derivado de isoxazolina como um inibidor contra várias caspases, a um processo para preparar o mesmo, e a uma composição terapêutica para prevenir inflamação e apoptose compreendendo o mesmo.
BRPI0413848A 2003-08-27 2004-08-26 composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, processo para preparar a composição terapêutica e uso de composto, ou de seu sal, ou de seu estereoisômero BRPI0413848B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2003-0059451 2003-08-27
KR20030059451 2003-08-27
PCT/KR2004/002139 WO2005021516A1 (en) 2003-08-27 2004-08-26 Caspase inhibitors containing isoxazoline ring

Publications (3)

Publication Number Publication Date
BRPI0413848A true BRPI0413848A (pt) 2006-10-24
BRPI0413848B1 BRPI0413848B1 (pt) 2019-04-30
BRPI0413848B8 BRPI0413848B8 (pt) 2021-05-25

Family

ID=36102769

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413848A BRPI0413848B8 (pt) 2003-08-27 2004-08-26 composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, processo para preparar a composição terapêutica e uso de composto, ou de seu sal, ou de seu estereoisômero

Country Status (27)

Country Link
US (1) US7557133B2 (pt)
EP (1) EP1660464B1 (pt)
JP (1) JP4503017B2 (pt)
KR (1) KR100594544B1 (pt)
CN (1) CN1842521B (pt)
AP (1) AP2104A (pt)
AR (1) AR045503A1 (pt)
BR (1) BRPI0413848B8 (pt)
CA (1) CA2535711C (pt)
EA (1) EA012080B1 (pt)
EC (1) ECSP066378A (pt)
EG (1) EG25751A (pt)
HK (1) HK1092788A1 (pt)
IL (1) IL173638A (pt)
MA (1) MA27999A1 (pt)
MX (1) MXPA06002267A (pt)
MY (1) MY162110A (pt)
NO (1) NO335620B1 (pt)
NZ (1) NZ545216A (pt)
OA (1) OA13244A (pt)
PE (1) PE20050371A1 (pt)
TR (1) TR200600899T2 (pt)
TW (1) TWI346110B (pt)
UA (1) UA83240C2 (pt)
UY (1) UY28494A1 (pt)
WO (1) WO2005021516A1 (pt)
ZA (1) ZA200601586B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774999B1 (ko) * 2005-02-26 2007-11-09 주식회사 엘지생명과학 이소옥사졸린 유도체 및 그의 제조 방법
US7754909B1 (en) * 2005-04-06 2010-07-13 The Florida State University Research Foundation, Inc. Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20080042290A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리돈 구조를 포함하는 캐스파제 저해제
EP2186804B1 (en) * 2007-08-10 2015-06-17 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and pest control agent
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
ES2640814T3 (es) 2008-05-21 2017-11-06 Genesis Technologies Limited Inhibidores selectivos de caspasa y usos de los mismos
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX350825B (es) 2011-03-31 2017-09-22 Bayer Ip Gmbh 3-fenilisoxazolin-5-carboxamidas y 3-fenilisoxazolin-5-tioamidas de accion herbicida y fungicida.
ES2665301T3 (es) 2011-04-15 2018-04-25 Genesis Technologies Limited Inhibidores selectivos de cisteína proreasa y usos de los mismos
MX354745B (es) * 2012-09-25 2018-03-16 Bayer Cropscience Ag 3-fenilisoxazolin-5-carboxamidas 5-oxi-sustituidas y 3-fenilisoxazolin-5-tioamidas 5-oxi-sustituidas herbicidas y fungicidas.
WO2014048827A1 (de) * 2012-09-25 2014-04-03 Bayer Cropscience Ag Herbizid wirksame 3-phenylisoxazolinderivate
JP6397820B2 (ja) * 2012-09-25 2018-09-26 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 除草活性と殺菌活性を示す３−ヘテロアリール−イソオキサゾリン−５−カルボキサミド類及び３−ヘテロアリール−イソオキサゾリン−５−チオアミド類
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
CN105753853B (zh) 2014-12-16 2020-08-04 沈阳中化农药化工研发有限公司 一种含异恶唑啉的脲嘧啶类化合物及其用途
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US20190022043A1 (en) 2015-12-31 2019-01-24 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
JP2019530696A (ja) 2016-10-05 2019-10-24 ノバルティス アーゲー 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物
TWI764977B (zh) * 2017-01-23 2022-05-21 大陸商正大天晴藥業集團股份有限公司 作爲ｃａｓｐａｓｅ抑制劑的聯環化合物、含有其的藥物組合物及其應用
WO2018228986A1 (de) 2017-06-13 2018-12-20 Bayer Aktiengesellschaft Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von tetrahydro- und dihydrofurancarbonsäureamiden
DK3638665T3 (da) 2017-06-13 2021-10-11 Bayer Ag Herbicidt virksomme 3-phenylisoxazolin-5-carboxamider af tetrahydro- og dihydrofurancarboxylsyrer og -estere
BR112020003266A2 (pt) 2017-08-17 2020-10-13 Bayer Aktiengesellschaft 3-fenil-5-trifluorometilisoxazolina-5-carboxamidas herbicidamente ativas de ésteres e ácidos ciclopentilcarboxílicos
WO2019145245A1 (de) 2018-01-25 2019-08-01 Bayer Aktiengesellschaft Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von cyclopentenylcarbonsäurederivaten
CN113631038B (zh) 2019-03-12 2023-06-30 拜耳公司 除草活性的含s环戊烯基羧酸酯的3-苯基异噁唑啉-5-甲酰胺
EP3939976B1 (en) * 2019-04-19 2024-05-01 Lg Chem, Ltd. Prodrug of caspase inhibitor
WO2020222541A1 (ko) * 2019-04-30 2020-11-05 주식회사 엘지화학 캐스파제 저해제의 프로드럭
WO2020242234A1 (ko) * 2019-05-31 2020-12-03 주식회사 엘지화학 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법
TW202237143A (zh) 2020-12-10 2022-10-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
CN114908028B (zh) * 2022-04-19 2024-05-31 杭州师范大学 一种双相体系下化学酶法级联催化腈类化合物的一锅法合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738486B2 (ja) * 1992-11-20 1998-04-08 ファイザー製薬株式会社 抗炎症剤としての新規なイソオキサゾリン類
ES2104424T3 (es) * 1993-11-26 1997-10-01 Pfizer Compuestos de isoxazolina como agentes antiinflamatorios.
DE69422061T2 (de) * 1993-11-26 2000-03-30 Pfizer, Inc. 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
DE60013147T2 (de) * 1999-09-17 2005-08-11 Lg Chem Investment, Ltd. Caspase-hemmer
AU5762899A (en) * 1999-09-17 2001-04-24 Lg Chemical Ltd. Caspase inhibitor

Also Published As

Publication number Publication date
KR100594544B1 (ko) 2006-06-30
TW200512199A (en) 2005-04-01
CN1842521B (zh) 2012-09-05
CA2535711C (en) 2011-07-05
EG25751A (en) 2012-06-25
UY28494A1 (es) 2005-02-28
ZA200601586B (en) 2007-05-30
EA012080B1 (ru) 2009-08-28
TWI346110B (en) 2011-08-01
WO2005021516A1 (en) 2005-03-10
CN1842521A (zh) 2006-10-04
BRPI0413848B1 (pt) 2019-04-30
AR045503A1 (es) 2005-11-02
EP1660464A1 (en) 2006-05-31
IL173638A0 (en) 2006-07-05
JP4503017B2 (ja) 2010-07-14
AP2006003509A0 (en) 2006-02-28
EP1660464B1 (en) 2015-02-25
ECSP066378A (es) 2006-08-30
KR20050022364A (ko) 2005-03-07
IL173638A (en) 2011-12-29
OA13244A (en) 2007-01-31
US7557133B2 (en) 2009-07-07
US20060223848A1 (en) 2006-10-05
PE20050371A1 (es) 2005-08-17
MA27999A1 (fr) 2006-07-03
MXPA06002267A (es) 2006-05-17
EA200600465A1 (ru) 2006-08-25
BRPI0413848B8 (pt) 2021-05-25
CA2535711A1 (en) 2005-03-10
UA83240C2 (ru) 2008-06-25
AU2004268895A1 (en) 2005-03-10
NO20061362L (no) 2006-03-24
AP2104A (en) 2010-02-06
NO335620B1 (no) 2015-01-12
HK1092788A1 (en) 2007-02-16
MY162110A (en) 2017-05-31
TR200600899T2 (tr) 2006-09-21
EP1660464A4 (en) 2008-11-26
JP2007503429A (ja) 2007-02-22
NZ545216A (en) 2009-06-26

Similar Documents

Publication Publication Date Title
BRPI0413848A (pt) composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, método para prevenir inflamação e apoptose, e, uso de composto inibidor de caspase, ou de seu sal, ou de seu estereoisÈmero
CR9580A (es) Inhibidores de la actividad akt
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
BRPI0412763A (pt) formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
CR8507A (es) Derivados de 2- piridiniletilbenzamida
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
AR060089A1 (es) Tratamiento del dolor
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
HN2003000063A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades.
BRPI0508333A (pt) uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
CO6210702A2 (es) Derivado de pirazolopirimidina
CR9539A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer
NO20032411D0 (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
UY26814A1 (es) Método y composición
BRPI0415824A (pt) inibidores de catepsina s
UY28419A1 (es) Compuestos 5-ariltetrazol, composiciones de los mismos y sus usos
WO2003090737A3 (en) Methods and compositions for treatment of cancer pain

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 261/04; A61P 29/00

Ipc: C07D 261/04 (2011.01), A61P 29/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: LG LIFE SCIENCES LTD. (KR)

B25G Requested change of headquarter approved

Owner name: LG LIFE SCIENCES LTD. (KR)

B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD (KR)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16D Grant of patent or certificate of addition of invention cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2521 DE 30/04/2019 POR TER SIDO INDEVIDA.

B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF